<DOC>
	<DOC>NCT01401114</DOC>
	<brief_summary>This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Wellnara for postmenopausal osteoporosis. The objective of this study is to assess safety and efficacy of using Wellnara in clinical practice. A total 400 patients will be recruited and followed 3 years since starting Wellnara administration.</brief_summary>
	<brief_title>Wellnara Post-marketing Surveillance in Japan</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<criteria>Patients who received Wellnara for postmenopausal osteoporosis Patients who are contraindicated based on the product label</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Wellnara</keyword>
	<keyword>Postmenopausal osteoporosis</keyword>
</DOC>